Modulation of pathogenicity

1. A compound of Formula (XIII), and/or a pharmaceutically acceptable salt, thereof:

wherein

A 7 is independently C═O, C═S, SO 2 , CH—OR 13 , C═NR 12 , or CH 2 —CHOR 13 ;

A 8 is independently C(R 14 ) 2 , O, S, or NR 12 ;

A 9 is independently C═O, C═S, SO 2 , CH—OR 13 , C═NR 12 , or CH 2 —CHOR 13 ;

m is 0, or 1;

q is 1;

r is 1;

R 12 is independently H, CH 3 , CH 2 —CH 3 , C 6 H 5 , OCH 3 , OCH 2 —CH 3 , OH, or SH;

R 13 is independently H, CH 3 , or CH 2 —CH 3 ;

R 14 is independently H, alkyl, alkoxy, OH, or SH;

A 5 is an optionally substituted C 3 -C 16 -alkyl group by one or more substituents R 3 ,

A 6 is an optionally substituted thiazole group, which can optionally be substituted by one or more substituents R 8 , R 8′ , or R 9 ,

R 8 , R 8′ , R 9 is independently methyl, ethyl, t-butyl, CN, halogen, haloalkoxy, haloalkyl, OH, alkoxy, NR 4 R 5 , or COOR 4 ;

R 3 is independently OR 4 , SR 4 , hydroxyalkyl, hydroxyalkylamino, cycloalkyl, halogen, haloalkyl, haloalkyloxy, NO 2 , CN, SO 2 NR 4 R 5 , CONR 4 R 5 , COR 4 , CO 2 R 4 , SO 2 R 4 , SO 3 R 4 , NR 4 R 5 , alkyl, aryl or heteroaryl;

R 4 is H, alkyl, cycloalkyl, aryl or heteroaryl; and

R 5 is H, O-alkyl, O-aryl, alkyl, heteroaryl or aryl.

2. The compound according to claim 1 wherein A 5 is an optionally substituted C 6 -C 11 alkyl group.

3. The compound according to claim 1 wherein A 8 is CH 2 .

4. The compound according to claim 1 wherein A 7 is C═O and A 9 is C═O.

5. The compound according to claim 1 wherein m is 1, A 7 is C═O, A 9 is C═O, A 8 is CH 2 , R 12 is H, and A 5 is an optionally substituted C 6 -C 11 alkyl group.

6. A pharmaceutical composition comprising a compound according to claim 1 , and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

7. The compound according to claim 1 , wherein A 6 is 1,3-thiazole.

8. A compound, and/or a pharmaceutically acceptable salt thereof, selected from the group consisting of